Clinuvel Pharmaceuticals Limited Stock Deutsche Boerse AG
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.500 EUR | 0.00% |
|
0.00% | -21.43% |
| Market Cap | 476M 336M 291M 272M 249M 469M 32B 3.19B 1.25B 16.04B 1.26B 1.23B 53.02B | P/E 2026 * |
13.3x | P/E 2027 * | 12.6x |
|---|---|---|---|---|---|
| Enterprise Value | 223M 158M 136M 127M 117M 220M 15.01B 1.49B 587M 7.52B 592M 579M 24.88B | EV / Sales 2026 * |
2.25x | EV / Sales 2027 * | 1.83x |
| Free-Float |
83.79% | Yield 2026 * |
0.65% | Yield 2027 * | 0.85% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| 1 month | -7.56% | ||
| 3 months | -3.51% | ||
| 6 months | -16.67% | ||
| Current year | -21.43% |
| 1 week | 5.3 |  | 5.5 |
| 1 month | 5.3 | | 6.4 |
| Current year | 5.1 | | 7.39 |
| 1 year | 5.1 | | 7.68 |
| 3 years | 4.8 | | 12.68 |
| 5 years | 4.8 | | 27 |
| 10 years | 3.27 | | 27 |
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | - | - | 336M | |
| +1.59% | +2.85% | +39.32% | +0.52% | 78.32B | |
| +2.77% | +4.78% | -0.98% | +28.10% | 51.1B | |
| -0.84% | +0.09% | +20.92% | +175.02% | 49.18B | |
| -0.13% | +7.42% | -49.33% | -50.09% | 44.71B | |
| +0.80% | +2.46% | +59.13% | -24.15% | 30.72B | |
| +1.84% | +0.87% | +53.80% | +86.83% | 24.44B | |
| +9.86% | +7.94% | +126.53% | -40.68% | 23.62B | |
| +4.29% | +9.40% | +3.95% | +230.49% | 21.05B | |
| +1.66% | -3.70% | +66.13% | +121.72% | 16.61B | |
| Average | +2.18% | +4.08% | +35.50% | +58.64% | 37.75B | |
| Weighted average by Cap. | +1.88% | +4.29% | +26.94% | +44.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.21M 70.07M 60.61M 56.6M 51.92M 97.65M 6.67B 664M 261M 3.34B 263M 257M 11.05B | 105M 73.88M 63.9M 59.68M 54.74M 103M 7.03B 700M 275M 3.52B 277M 271M 11.65B |
| Net income | 35.72M 25.23M 21.82M 20.38M 18.69M 35.16M 2.4B 239M 93.84M 1.2B 94.73M 92.66M 3.98B | 37.66M 26.6M 23.01M 21.49M 19.71M 37.07M 2.53B 252M 98.94M 1.27B 99.88M 97.69M 4.19B |
| Net Debt | -253M -178M -154M -144M -132M -249M -16.98B -1.69B -664M -8.51B -670M -656M -28.14B | -285M -201M -174M -162M -149M -280M -19.13B -1.9B -748M -9.59B -755M -738M -31.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-07 | €5.500 | 0.00% | 0 |
| 26-08-06 | €5.500 | +3.77% | 0 |
| 26-08-05 | €5.300 | 0.00% | 0 |
| 26-08-04 | €5.300 | 0.00% | 0 |
| 26-08-03 | €5.300 | -3.64% | 395 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CUV Stock
- UR9 Stock
Select your edition
All financial news and data tailored to specific country editions
